Current stock page

Financial Data

PCVX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

PCVXVaxcyte, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$63.37−$1.32 (−2.04%)

Latest quote

  • Momentum
    81
  • Value
    —
  • Quality
    54
  • Risk resilience
    53
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$0$0$0$0$0$0
Gross Profit$0$0-$5.85M$4.99M$0-$4.99M$0$0
Operating Income-$308.27M-$302.78M-$345.85M-$274.28M-$242.38M-$226.22M-$180.79M-$162.17M
Net Income-$297.06M-$284.3M-$320.62M-$246.51M-$212.83M-$166.57M-$140.72M-$137.08M
EPS-$1.99-$1.97-$2.3-$1.81-$1.56-$1.22-$1.04-$1.12
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$224.08M-$513.1M-$280.63M-$224.83M-$143.31M-$121.17M-$166.27M-$111.4M
Capital Expenditure-$4.96M-$19.37M-$14.79M$5.57M-$12.05M$19.52M-$26.75M-$30.03M
Free Cash Flow-$229.04M-$532.46M-$295.42M-$219.26M-$155.35M-$101.65M-$193.03M-$141.43M
Net Cash Provided By Operating Activities-$224.08M-$513.1M-$280.63M-$224.83M-$143.31M-$121.17M-$166.27M-$111.4M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$2.99B$3.14B$3.35B$3B$3.17B$3.31B$3.38B$3.51B
Total Debt$221.84M$115.45M$116.3M$117.48M$84.44M$85.85M$87.21M$71.11M
Cash And Cash Equivalents$125.47M$183.19M$260.84M$173.96M$281.08M$306.74M$346.85M$387.88M
Total Liabilities$499.92M$380.21M$352.29M$317.21M$278.72M$234.03M$178.08M$205.5M
Total Stockholders Equity$2.49B$2.76B$3B$2.69B$2.89B$3.07B$3.2B$3.31B
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio3.72.932.663.111.951.461.232.95
P/S ratio————————
Debt To Equity0.090.040.040.040.030.030.030.02
Free Cash Flow Yield-13.84%-14.88%-9.69%-8.02%-10.50%-11.92%-15.25%-5.93%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio3.72.932.663.111.951.461.232.95
P/S ratio————————
Return On Equity-46.14%-38.59%-31.59%-28.55%-22.72%-17.83%-15.93%-14.03%
Debt To Equity0.090.040.040.040.030.030.030.02

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-7.85x
Pb3.79x
EPS Growth Yoy-27.56%
Gross Margin0.00%
Operating Margin0.00%
ROE-42.04%
ROIC-45.41%
Debt To Equity0.09
FCF Yield-12.72%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$63.37
Volume623,630
RSI (14)49.5
MACD0.75
MACD signal0.58
MACD histogram0.17
ADX (14)26.56
SMA (50)$62.24
SMA (200)$57.70
ATR (14)$3.38
Historical volatility (annualized)58.27%
Volume (20-day average)1.89M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score53/100
Beta1.26
Annual volatility56.19%
Max Drawdown-27.95%
Sharpe Ratio0.79
VaR (95%, 1-day)-4.06%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

PCVX Financial Data FAQ

What is Vaxcyte, Inc.'s revenue?

Vaxcyte, Inc.'s revenue is one of the core financial data points for PCVX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Vaxcyte, Inc.'s revenue growing?

Revenue growth shows whether Vaxcyte, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is PCVX's EPS?

PCVX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Vaxcyte, Inc.'s net income?

Vaxcyte, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Vaxcyte, Inc. generate?

Free cash flow shows how much cash Vaxcyte, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Vaxcyte, Inc. have?

Cash and debt help frame PCVX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.